Check with your doctor right away if you have watery stool that does not go away, stomach pain, and fever while taking this medicine.
Lansoprazole may increase your risk of having fractures of the hip, wrist, and spine. This is more likely if you have osteoporosis, if you are 50 years of age and older, if you receive high doses of this medicine, or if you use it for one year or more. Cutaneous or systemic lupus erythematosus may occur or get worse in patients receiving a PPI. Call your doctor right away if you have joint pain or a skin rash on your cheeks or arms that gets worse when exposed to the sun.
This medicine may cause hypomagnesemia low magnesium in the blood. Check with your doctor right away if you have convulsions seizures , fast, racing, or uneven heartbeat, muscle spasms tetany , tremors, or unusual tiredness or weakness. This medicine may increase your risk for fundic gland polyps abnormal tissue growth in the upper part of your stomach. This is more likely if you are receiving this medicine for more than 1 year. Talk to your doctor if you have concerns.
Do not stop taking this medicine without first checking with your doctor, or unless told to do so by your doctor. Before you have any medical tests, tell the medical doctor in charge that you or your child are taking this medicine. The results of some tests may be affected by this medicine. Do not take other medicines unless they have been discussed with your doctor.
John's wort or vitamin supplements. Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine.
Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:. Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional. Call your doctor for medical advice about side effects.
Dicyclomine: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Digoxin: Moderate Lansoprazole or other proton pump inhibitors PPIs can affect digoxin absorption due to their long-lasting effect on gastric acid secretion. Additionally, PPIs may slightly increase digoxin bioavailability.
Patients with digoxin serum levels at the upper end of the therapeutic range may need to be monitored for potential increases in serum digoxin levels when a PPI is coadministered with digoxin. Finally, PPIs have been associated with hypomagnesemia. Becuase, low serum magnesium may lead to irregular heartbeat and increase the likelihood of serious cardiac arrhythmias, clinicians should monitor serum magnesium concentrations periodically in patients taking a PPI and digoxin concomitantly.
Diphenoxylate; Atropine: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Lansoprazole is a substrate for CYP3A4. The concomitant administration of dronedarone and CYP3A substrates may result in increased exposure of the substrate and should, therefore, be undertaken with caution.
Elagolix: Minor Coadministration of elagolix with lansoprazole may theoretically increase plasma concentrations of lansoprazole. Monitor for lansoprazole-related adverse effects during coadministration with elagolix. Elagolix; Estradiol; Norethindrone acetate: Minor Coadministration of elagolix with lansoprazole may theoretically increase plasma concentrations of lansoprazole. Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide: Minor Use caution when administering cobicistat and lansoprazole concurrently.
Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate: Minor Use caution when administering cobicistat and lansoprazole concurrently. Enzalutamide: Major Avoid coadministration of enzalutamide with lansoprazole due to decreased plasma concentrations of lansoprazole. Erlotinib: Major Avoid coadministration of erlotinib with lansoprazole if possible due to decreases in erlotinib plasma concentrations.
Erlotinib solubility is pH dependent and solubility decreases as pH increases. Coadministration of erlotinib with medications that increase the pH of the upper gastrointestinal tract may decrease the absorption of erlotinib. Separation of doses may not eliminate the interaction since proton pump inhibitors affect the pH of the upper GI tract for an extended period of time.
Increasing the dose of erlotinib is also not likely to compensate for the loss of exposure. If these drugs are used together, monitor for escitalopram-associated adverse reactions. It is unclear that the theoretical interaction would result in a net increase or decrease in PPI action. Some manufacturers recommend avoiding the coadministration of hepatic cytochrome P enzyme inducers and PPIs.
If eslicarbazepine and PPI must be used together, monitor the patient closely for signs and symptoms of GI bleeding or other signs and symptoms of reduced PPI efficacy, or for signs of PPI side effects. Ethacrynic Acid: Moderate Proton pump inhibitors have been associated with hypomagnesemia.
Concomitant use of fenofibric acid with CYP2C19 substrates, such as lansoprazole, has not been formally studied. Fenofibric acid may theoretically increase plasma concentrations of CYP2C19 substrates and could lead to toxicity for drugs that have a narrow therapeutic range. Monitor the therapeutic effect of lansoprazole during coadministration with fenofibric acid.
Flavoxate: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Fluvoxamine: Moderate Fluvoxamine is a major inhibitor of the cytochrome P enzyme 2C Several proton pump inhibitors, including lansoprazole, are primary substrates of the CYP2C19 enzyme. Reduced metabolism and resulting elevated plasma concentrations of these PPIs may occur if combined with fluvoxamine.
Food: Major Administer on an empty stomach, 30 to 60 minutes before meals. Furosemide: Moderate Proton pump inhibitors have been associated with hypomagnesemia. Gefitinib: Major Avoid coadministration of lansoprazole with gefitinib if possible due to decreased exposure to gefitinib, which may lead to reduced efficacy. If concomitant use is unavoidable, take gefitinib 12 hours after the last dose or 12 hours before the next dose of lansoprazole.
Gefitinib exposure is affected by gastric pH. Glycopyrrolate: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Glycopyrrolate; Formoterol: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e.
Homatropine; Hydrocodone: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Hydantoins: Moderate Some manufacturers recommend avoiding the coadministration of hepatic cytochrome P enzyme inducers and proton pump inhibitors PPIs.
Phenytoin induces hepatic cytochrome P enzymes, including those responsible for the metabolism of PPIs e. If phenytoin and PPIs must be used together, monitor the patient closely for signs and symptoms of GI bleeding or other signs and symptoms of reduced PPI efficacy.
Hyoscyamine: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e.
Indacaterol; Glycopyrrolate: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Infigratinib: Major Avoid coadministration of infigratinib and gastric acid-reducing agents, such as proton pump inhibitors PPIs. Coadministration may decrease infigratinib exposure resulting in decreased efficacy.
If necessary, infigratinib may be administered two hours before or ten hours after an H2-receptor antagonist or two hours before or after a locally acting antacid. Iron: Moderate The bioavailability of oral iron salts is influenced by gastric pH, and the concomitant administration of proton pump inhibitors can decrease iron absorption.
The non-heme ferric form of iron needs an acidic intragastric pH to be reduced to ferrous and to be absorbed. Iron salts and polysaccharide-iron complex provide non-heme iron. Proton pump inhibitors have long-lasting effects on the secretion of gastric acid and thus, increase the pH of the stomach. The increase in intragastric pH can interfere with the absorption of iron salts. Isavuconazonium: Moderate Concomitant use of isavuconazonium with lansoprazole may result in increased serum concentrations of lansoprazole.
Caution and close monitoring are advised if these drugs are used together. Isoniazid, INH; Pyrazinamide, PZA; Rifampin: Major Avoid coadministration of lansoprazole with rifampin due to the risk of decreased lansoprazole plasma concentrations which may decrease efficacy. Isoniazid, INH; Rifampin: Major Avoid coadministration of lansoprazole with rifampin due to the risk of decreased lansoprazole plasma concentrations which may decrease efficacy.
Itraconazole: Moderate When administering proton pump inhibitors with the mg itraconazole capsule and mg itraconazole tablet formulations, systemic exposure to itraconazole is decreased. Conversely, exposure to itraconazole is increased when proton pump inhibitors are administered with the 65 mg itraconazole capsule. Administer proton pump inhibitors at least 2 hours before or 2 hours after the mg capsule or mg tablet. Monitor for increased itraconazole-related adverse effects if proton pump inhibitors are administered with itraconazole 65 mg capsules.
Ketoconazole: Major Because ketoconazole requires an acidic pH for absorption, coadministration of a proton pump inhibitor PPI with ketoconazole can cause a notable decrease in the bioavailability of ketoconazole.
PPIs have a prolonged duration of action, and staggering their time of administration with ketoconazole by several hours may not prevent the drug interaction. An alternative imidazole antifungal should be chosen if any of these gastrointestinal medications are required.
If these drugs must be coadministered, administer ketoconazole tablets with an acidic beverage and closely monitor for breakthrough infection. Ledipasvir; Sofosbuvir: Major Solubility of ledipasvir decreases as gastric pH increases; thus, coadministration of ledipasvir; sofosbuvir with proton pump inhibitors PPIs may result in lower ledipasvir plasma concentrations. Ledipasvir can be administered with PPIs if given simultaneously under fasting conditions.
Letermovir: Moderate Plasma concentrations of lansoprazole could be increased when administered concurrently with letermovir. The magnitude of this interaction may be increased in patients who are also receiving cyclosporine. If these drugs are given together, monitor for lansoprazole-related adverse events. Letermovir is a moderate inhibitor of CYP3A4.
Lonafarnib: Moderate Monitor for lansoprazole-related adverse effects during coadministration with lonafarnib. Concurrent use may increase lansoprazole exposure.
Loop diuretics: Moderate Proton pump inhibitors have been associated with hypomagnesemia. Lopinavir; Ritonavir: Moderate Increased exposure to lansoprazole may occur during concurrent administration of ritonavir. Monitor patients for adverse effects of lansoprazole, such as electroylyte changes. In vitro, therapeutic doses of luliconazole inhibit the activity of CYP2C19 amd CYP3A4 and small systemic concentrations may be noted with topical application, particularly when applied to patients with moderate to severe tinea cruris.
No in vivo drug interaction trials were conducted prior to the approval of luliconazole. Lumacaftor; Ivacaftor: Moderate Lumacaftor; ivacaftor may reduce the efficacy of lansoprazole by substantially decreasing its systemic exposure.
If used together, a lansoprazole dosage adjustment may be necessary to obtain the desired therapeutic effect. Patients on chronic mefloquine therapy might be at increased risk of adverse reactions, especially patients with a neurological or psychiatric history. Mepenzolate: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e.
Mephobarbital: Moderate Monitor for decreased efficacy of lansoprazole if concomitant use of lansoprazole and barbiturates is necessary. Methohexital: Moderate Monitor for decreased efficacy of lansoprazole if concomitant use of lansoprazole and barbiturates is necessary. Methotrexate: Major Use caution when administering high-dose methotrexate to patients receiving proton pump inhibitors PPIs ; a temporary withdrawal of the PPI should be considered in some patients receiving high-dose methotrexate.
In two of these cases, delayed methotrexate elimination was observed when high-dose methotrexate was coadministered with PPIs but was not observed when methotrexate was coadministered with ranitidine. However, no formal drug interaction studies of methotrexate with ranitidine have been conducted.
Altered methotrexate elimination may not be present or problematic among patients who receive lower methotrexate doses. For example, coadministration of lansoprazole 30 mg daily and naproxen mg twice daily for 7 days to recipients of stable oral methotrexate doses 7. Specifically, the peak plasma concentration and area under the plasma concentration-time curve of methotrexate and 7-hydroxymethotrexate were within the 0.
Methscopolamine: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Methyclothiazide: Moderate Proton pump inhibitors have been associated with hypomagnesemia.
Metolazone: Moderate Proton pump inhibitors have been associated with hypomagnesemia. Mitotane: Moderate Use caution if mitotane and lansoprazole are used concomitantly, and monitor for decreased efficacy of lansoprazole and a possible change in dosage requirements.
Mitotane is a strong CYP3A4 inducer and lansoprazole is a CYP3A4 substrate; coadministration may result in decreased plasma concentrations of lansoprazole. Reduced systemic exposure of MPA after mycophenolate mofetil in the presence of a PPI appears to be due to impaired absorption of mycophenolate mofetil which may occur because of incomplete dissolution of mycophenolate mofetil in the stomach at elevated pH.
The clinical significance of reduced MPA exposure is unknown; however patients should be evaluated periodically if mycophenolate mofetil is administered with a PPI. Of note, MPA concentrations appear to be reduced in the initial hours after mycophenolate mofetil receipt but increase later in the dosing interval because of enterohepatic recirculation.
A second peak in the concentration-time profile of MPA is observed hours after dosing due to enterohepatic recirculation. For example, the hour plasma concentrations of MPA were similar among patients who received mycophenolate mofetil with or without omeprazole.
The biphasic plasma concentration-time course of MPA due to extensive enterohepatic circulation hampers therapeutic drug monitoring of MPA. The interaction does not appear to exist with Mycophenolate sodium Myfortic. Nelfinavir: Major Use of proton pump inhibitors with nelfinavir is not recommended. Coadministration may result in decreased nelfinavir exposure, subtherapeutic antiretroviral activity, and possibility resistant HIV mutations. Neratinib: Major Avoid concomitant use of neratinib with proton pump inhibitors due to decreased absorption and systemic exposure of neratinib; the solubility of neratinib decreases with increasing pH of the GI tract.
Nilotinib displays pH-dependent solubility with decreased solubility at a higher pH. PPIs inhibit gastric acid secretion and elevate the gastric pH. Increasing the dose is unlikely to compensate for the loss of nilotinib exposure; additionally, separating the administration of these agents may not eliminate the interaction as PPIs affect the pH of the upper GI tract for an extended period of time. Octreotide: Moderate Coadministration of oral octreotide with proton pump inhibitors PPIs may require increased doses of octreotide.
Coadministration of oral octreotide with drugs that alter the pH of the upper GI tract, including PPIs, may alter the absorption of octreotide and lead to a reduction in bioavailability.
This interaction has been documented with esomeprazole and can occur with the other PPIs. Ombitasvir; Paritaprevir; Ritonavir: Moderate Increased exposure to lansoprazole may occur during concurrent administration of ritonavir. Oritavancin: Moderate Coadministration of oritavancin and lansoprazole may result in increases or decreases in lansoprazole exposure and may increase side effects or decrease efficacy of lansoprazole. If these drugs are administered concurrently, monitor the patient for signs of toxicity or lack of efficacy.
Oxybutynin: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e. Pazopanib: Major Pazopanib displays pH-dependent solubility with decreased solubility at a higher pH.
The concomitant use of pazopanib and proton pump inhibitors PPIs that elevate the gastric pH may reduce the bioavailability of pazopanib. If a drug is needed to raise the gastric pH, consider use of a short-acting antacid; separate antacid and pazopanib dosing by several hours. Pentobarbital: Moderate Monitor for decreased efficacy of lansoprazole if concomitant use of lansoprazole and barbiturates is necessary.
Pexidartinib: Major Avoid coadministration of pexidartinib with lansoprazole as concurrent use may decrease pexidartinib exposure which may result in decreased therapeutic response. As an alternative to a proton pump inhibitor PPI , use locally-acting antacids or H2-receptor antagonists. Phenobarbital: Moderate Monitor for decreased efficacy of lansoprazole if concomitant use of lansoprazole and barbiturates is necessary.
Phenobarbital; Hyoscyamine; Atropine; Scopolamine: Moderate Monitor for decreased efficacy of lansoprazole if concomitant use of lansoprazole and barbiturates is necessary. Polyethylene Glycol; Electrolytes; Bisacodyl: Minor The concomitant use of bisacodyl oral tablets with drugs that raise gastric pH like proton pump inhibitors can cause the enteric coating of the bisacodyl tablets to dissolve prematurely, leading to possible gastric irritation or dyspepsia.
Posaconazole: Major The concurrent use of posaconazole immediate-release oral suspension and proton pump inhibitors PPIs should be avoided, if possible, due to the potential for decreased posaconazole efficacy. If used in combination, closely monitor for breakthrough fungal infections. PPIs increase gastric pH, resulting in decreased posaconazole absorption and lower posaconazole plasma concentrations. The pharmacokinetics of posaconazole delayed-release tablets and oral suspension are not significantly affected by PPIs.
Additionally, posaconazole is a potent inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of many PPIs dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole. Coadministration may result in increased plasma concentration of the PPIs. Primidone: Moderate Monitor for decreased efficacy of lansoprazole if concomitant use of lansoprazole and barbiturates is necessary. Propantheline: Moderate The American College of Gastroenterology states that the effectiveness of proton pump inhibitors PPIs may be theoretically decreased if given with other antisecretory agents e.
Rifampin: Major Avoid coadministration of lansoprazole with rifampin due to the risk of decreased lansoprazole plasma concentrations which may decrease efficacy. Rifapentine: Major Avoid concomitant use of lansoprazole and rifapentine as lansoprazole exposure may be decreased, reducing its efficacy. Risedronate: Moderate Use of proton pump inhibitors PPIs with delayed-release risedronate tablets Atelvia is not recommended.
Saquinavir: Major Coadministration with omeprazole results in significantly increased saquinavir concentrations. A similar interaction is expected with all proton pump inhibitors PPIs. If saquinavir must be administered with PPIs, the patient should be closely monitored for saquinavir-related toxicities, including gastrointestinal symptoms, increased triglycerides, and deep vein thrombosis DVT.
Coadministration with omeprazole results in significantly increased saquinavir concentrations. You and your doctor should monitor certain health issues. This can help make sure that you stay safe while you take this drug. These issues include:. Not every pharmacy stocks this drug. When filling your prescription, be sure to call ahead to make sure your pharmacy carries it.
Many insurance companies require a prior authorization for this drug. This means your doctor will need to get approval from your insurance company before your insurance company will pay for the prescription.
There are other drugs available to treat your condition. Some may be better suited for you than others. Talk to your doctor about other drug options that may work for you. Disclaimer: Healthline has made every effort to make certain that all information is factually correct, comprehensive, and up-to-date. However, this article should not be used as a substitute for the knowledge and expertise of a licensed healthcare professional.
You should always consult your doctor or other healthcare professional before taking any medication. The drug information contained herein is subject to change and is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.
The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses. Do you deal with heartburn more than twice a week? You could be dealing with GERD. Learn what causes it, and what treatment options are available. Learn about potential problems associated with rheumatoid arthritis and pregnancy, including triggers, preeclampsia, premature birth, and low birth…. Eating the right kinds of food is key to controlling your acid reflux and gastroesophageal reflux disease GERD.
Learn more here. Heartburn is often treated with medication, but simple dietary and lifestyle changes can help, too. Here are 14 home remedies for heartburn and acid…. Both gastritis and duodenitis have the same causes and treatments. Gastritis is inflammation of your stomach lining. Duodenitis is inflammation of the…. But certain foods may help fight the cause of your stomach ulcer.
Gastric and duodenal ulcers are both types of peptic ulcers. These ulcers can cause different symptoms, depending on where they are. A peptic ulcer on…. Stomach ulcers are a relatively common and irritating medical condition. This article lists 9 scientifically backed natural ulcer remedies. You should not use this medicine if you are allergic to lansoprazole, or if you take any medicine that contains rilpivirine Edurant, Complera, Odefsey.
Do not use over-the-counter lansoprazole Prevacid OTC without the advice of a doctor if you have:. Some forms of lansoprazole may contain phenylalanine. Tell your doctor if you have phenylketonuria PKU. You may be more likely to have a broken bone in your hip, wrist, or spine while taking a proton pump inhibitor long-term or more than once per day.
Talk with your doctor about ways to keep your bones healthy. Do not give lansoprazole to a child younger than 1 year old. Prevacid OTC is not approved for use by anyone younger than 18 years old. Ask a doctor before using this medicine if you are pregnant or breastfeeding.
Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Taking lansoprazole long-term may cause you to develop stomach growths called fundic gland polyps. Talk with your doctor about this risk. If you use lansoprazole for longer than 3 years, you could develop a vitamin B deficiency. Talk to your doctor about how to manage this condition if you develop it. This is not a complete list of side effects and others may occur.
Call your doctor for medical advice about side effects. This medicine can cause diarrhea, which may be a sign of a new infection.
0コメント